Abstract 79P
Background
Neoantigens, a type of tumor-specific antigens derived from non-synonymous mutations, have become attractive targets for cancer immunotherapy. Approaches targeting private neoantigens derived from mutations that are unique to individual patients’ tumors are costly, labor-intensive and could lead treatment resistance due to antigen loss during clonal evolution. By contrast, vaccines targeting public neoantigens derived from recurrent mutations in cancer driver genes could be designed as “off-the-shelf” vaccines and would be broadly applicable to many cancer patients. However, this therapeutic approach relies on the accurate selection of highly recurrent mutations and identification of immunogenic neoantigens.
Methods
Here, we developed a pipeline with both computational prediction tools and experimental validation assays, known as NEX-NEO to expedite the identification of public neoantigens in 100 patients with colorectal cancer (n=50) and lung cancer (n=50). Furthermore, we developed a robust screening assay using K562 cells expressing HLA-A*11:01 as antigen presenting cells to validate their immunogenicity.
Results
By using NEX-NEO, we constructed an off-the-shelf neoantigen panel of 67 neoantigen candidates which cover 63% and 49% of colorectal and lung cancer patients, respectively. Of the 47 candidates for HLA-A1101 ligand, we identified 23 (48%) immunogenic peptides which are capable of activating CD8 T cells to produce IFN-γ and Granzyme B in PBMC from 10 healthy donors.
Conclusions
In conclusion, our study proposed a novel pipeline for the development of off-the-shelf neoantigen vaccines that could benefit a large proportion of cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Genetics Institute.
Funding
Nexcalibur Therapeutics.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract